C4 Therapeutics (CCCC) Insider Laura Bessen Buys 62,000 Shares
Laura Bessen bought 62,000 shares of C4 Therapeutics, Inc. on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Laura Bessen bought 62,000 shares of C4 Therapeutics, Inc. ($CCCC) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CCCC is up 2.1% after 1 week, down 20.0% after 1 month and down 34.8% to date (from the $4.25 close on Jun 24, 2026).
CCCC
C4 Therapeutics, Inc.
Key Points
- Laura Bessen purchased 62,000 shares of C4 Therapeutics, Inc. at a price of $4.26 per share on June 24, 2026.
- C4 Therapeutics is trading near its 52-week high of $5.17, which highlights the company's recent performance.
- JP Morgan recently initiated coverage of C4 Therapeutics with an Overweight rating and a $10 price target on October 9, 2026.
Get $CCCC trade alerts by text
We text you when insiders, Congress or big funds trade $CCCC. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated C4 Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at C4 Therapeutics, Inc.
Laura Bessen bought 62,000 shares of C4 Therapeutics, Inc. (NasdaqGS: CCCC) on June 24, 2026. The shares were purchased at a price of $4.26 each, bringing the total value of the transaction to about $263,220 based on the stock's spot price at the time.
Other Insiders Join In
Bessen's purchase is part of a larger trend among C4 Therapeutics insiders. On the same day, Ronald Cooper, Utpal Koppikar, Donna Roy Grogan, Owen Hughes, Stephen Fawell, and Steven Hoerter each bought 62,000 shares. This collective buying suggests strong confidence in the company’s future direction.
How C4 Therapeutics, Inc. Stock Has Traded
C4 Therapeutics is currently trading close to its 52-week high of $5.17. The stock has shown significant movement recently, with a previous close of $3.39. This upward momentum could reflect positive sentiment around the company's ongoing projects and future potential.
Analysts Set New Price Targets
On October 9, 2026, JP Morgan initiated coverage of C4 Therapeutics with an Overweight rating and set a price target of $10. This endorsement from analysts suggests that they see potential for growth in the company's stock price based on its fundamentals and market position.
About C4 Therapeutics
C4 Therapeutics, Inc. is a biotechnology company based in Watertown, Massachusetts. It focuses on developing innovative therapies to degrade harmful proteins, with key products aimed at treating cancers like multiple myeloma and non-small cell lung cancer.
What's Ahead for C4 Therapeutics, Inc.
Investors will be watching for C4 Therapeutics' next earnings report scheduled for November 5, 2026. With recent insider activity and analyst interest, the company may be in a position to share positive developments in its ongoing projects.
Related Filing Alerts
Source: Laura Bessen's Form 4 filing on $CCCC (Jun 24, 2026). Find the original filing: CCCC Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts